Regencell Bioscience Holdings Limited (RGC) P/B ratio
Regencell Bioscience Holdings Limited (RGC) trades at 169.0× its book value per share at the end of fiscal 2026. At the end of fiscal 2026 (June 30, 2026) its P/B ratio was 226.2×. Today's figure is 25.3% below the fiscal 2026 year-end. Figures as of 18 Nov 2026, 10:34 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/B ratio today
- 169.0×
- P/B ratio, fiscal 2026
- 226.2×
- Highest on record
- 226.2×fiscal 2026
- Lowest on record
- 5.3×fiscal 2024
- Fiscal years on record
- 42022–2026
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Regencell Bioscience Holdings Limited P/B ratio, in more detail
Across the 4 fiscal year-ends on record (2022–2026), the highest was 226.2× in fiscal 2026 and the lowest 5.3× in fiscal 2024. Today's P/B ratio is higher than at 75% of the 4 fiscal year-ends on record; their median is 25.4×.
P/B ratio at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
Regencell Bioscience Holdings Limited P/B ratio, year by year
| Fiscal year | P/B ratio | Change | Year ended | Share price at year-end | Book value per share |
|---|---|---|---|---|---|
| Today | 169.0× | — | $4.55 | — | |
| 2026 | 226.2× | — | $6.09 | $0.03 | |
| 2024 | 5.3× | 78.7% down | $0.09 | $0.02 | |
| 2023 | 24.9× | 4.0% down | $0.61 | $0.02 | |
| 2022 | 26.0× | — | $0.91 | $0.04 | |
| 2021 | — | — | — | -$0.01 | |
| 2020 | — | — | — | -$0.01 | |
| 2019 | — | — | — | -$1,209,553.29 |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.
How to read it
It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.
Regencell Bioscience Holdings Limited, figure by figure
- Regencell Bioscience Holdings Limited market cap
- Regencell Bioscience Holdings Limited revenue
- Regencell Bioscience Holdings Limited earnings
- Regencell Bioscience Holdings Limited earnings per share (EPS)
- Regencell Bioscience Holdings Limited P/E ratio
- Regencell Bioscience Holdings Limited P/S ratio
- Regencell Bioscience Holdings Limited free cash flow
- Regencell Bioscience Holdings Limited operating margin
- Regencell Bioscience Holdings Limited dividend
- Regencell Bioscience Holdings Limited shares outstanding
- Regencell Bioscience Holdings Limited total debt
- Regencell Bioscience Holdings Limited cash on hand
- Regencell Bioscience Holdings Limited total assets
- Regencell Bioscience Holdings Limited return on equity (ROE)
- Regencell Bioscience Holdings Limited return on invested capital (ROIC)
Regencell Bioscience Holdings Limited (RGC) overview: price, valuation and scorecard
Regencell Bioscience Holdings Limited P/B ratio: questions and answers
What is Regencell Bioscience Holdings Limited's P/B ratio?
Regencell Bioscience Holdings Limited (RGC) trades at 169.0× its book value per share at the end of fiscal 2026. At the end of fiscal 2026 (June 30, 2026) its P/B ratio was 226.2×.
Is Regencell Bioscience Holdings Limited's P/B ratio high or low compared with its own history?
Today's P/B ratio is higher than at 75% of the 4 fiscal year-ends on record; their median is 25.4×.
What are the highest and lowest P/B ratio figures on record for Regencell Bioscience Holdings Limited?
Across the 4 fiscal year-ends on record (2022–2026), the highest was 226.2× in fiscal 2026 and the lowest 5.3× in fiscal 2024.
How is Regencell Bioscience Holdings Limited's P/B ratio calculated?
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B. For Regencell Bioscience Holdings Limited it is on record here for 4 fiscal years, 2022 to 2026.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/B ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Piotroski F-score: the nine tests and what they show
The Piotroski F-score is a 0–9 count of simple accounting tests a company passes: four on profitability, three on debt, liquidity and share issuance, two on operating efficiency. Joseph Piotroski's 2000 paper found that among cheap, high book-to-market stocks, high scorers went on to beat low scorers. It is a screen of financial health, not a valuation.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Regencell Bioscience Holdings Limited (RGC) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/RGC/pb-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.